|
Synonyms: Apo-2 ligand (Apo-2L)
Compound class:
Endogenous peptide in human, mouse or rat
Comment: TRAIL is a cytokine of the tumor necrosis factor (TNF) ligand family. TRAIL binds to several TNF family receptors, activating MAPK8/JNK, caspase 8, and caspase 3. Its interaction with death receptors on tumor cells triggers apoptosis. Binding to decoy receptors may neutralise TRAIL activity. Because TRAIL exhibits much stronger apoptotic activity than other TNF family members, kills tumor cells more effectively than normal cells, and presents less risk of inducing an inflammatory repsonse following systemic administration, use of TRAIL as an anti-cancer therapeutic has been widely examined. Huang et al. (2017) [2] describe the development and potent anti-tumor activity of a TRAIL fusion protein nanoparticle formulation in a xenograft model [1]. To date, no pharmaceutical agents targeting TRAIL or its receptors in cancer have been approved.
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. (2008)
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther, 7 (4): 851-61. [PMID:18413798] |
|
2. Huang K, Duan N, Zhang C, Mo R, Hua Z. (2017)
Improved antitumor activity of TRAIL fusion protein via formation of self-assembling nanoparticle. Sci Rep, 7: 41904. [PMID:28225020] |
|
3. Zhou T, Ichikawa K, Kimberley RP, Koopman WJ. (2001)
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof. Patent number: WO2001083560. Assignee: Uab Research Foundation. Priority date: 02/05/2000. Publication date: 08/11/2001. |
